Cagent Vascular

Executive Summary

Cagent Vascular is a private medical device company pioneering next-generation angioplasty balloons with its proprietary Serration Technology. Its lead product, the Serranator, is designed to treat peripheral artery disease (PAD) by gently remodeling arteries to achieve optimal lumen gain and improve procedural outcomes. The company is based in Wayne, Pennsylvania, and has been developing this technology since its founding in 2012. While the company has not disclosed total funding or valuation, it operates in the large and growing PAD treatment market, competing with traditional angioplasty balloons and drug-coated balloons. The Serranator's unique mechanism may offer advantages in vessel preparation without the need for drug coatings, potentially reducing restenosis and complications. However, as a private company with limited public information, Cagent Vascular's progress remains largely confidential. The next major milestones likely involve clinical data readouts or regulatory clearances to expand commercialization.

Upcoming Catalysts (preview)

• TBDFDA 510(k) clearance for Serranator in a new indication or expanded claims70% success
• TBDPublication of pivotal clinical trial results demonstrating superior efficacy over standard balloons60% success
• TBDStrategic partnership or distribution agreement with a larger cardiovascular company50% success